LEASANTON, Calif.—The Cooper Companies, Inc. (NYSE: COO) announced financial results for the fiscal fourth quarter and full year ended Oct. 31, 2016. The company said that its Q4 revenue rose 14 percent year-over-year to $518.7 million while its fiscal revenue increased 9 percent to $1,966.8 million.

Commenting on the results, Robert S. Weiss, Cooper’s president and CEO said, “I am pleased to report record revenue and free cash flow for the year. We accomplished this through market share gains, a successful push into the 1-Day silicone hydrogel space, growth in our Biofinity franchise and a very strong year in our CooperSurgical business. We enter fiscal 2017 with momentum and are well positioned for sustained growth in each of our businesses going forward.”

For the fourth quarter period, revenues for CooperVision (CVI) division were $411.7 million, up 10 percent from the prior year’s quarter, up 11 percent in constant currency. For that period, Cooper reported that its toric business rose 14 percent to $126.1 million while multifocals’ revenue rose 9 percent to $42.6 million and single-use spheres climbed 17 percent to $110.4 million. Sales in the Americas were up 8 percent to $168.1 million for the fourth quarter compared to the prior year.

CooperSurgical (CSI) revenues for the quarter climbed 30 percent to $106.9 million, including office and surgical products as well as fertility products.

CooperVision’s fiscal year revenue was $1,577.2 million, a gain of 6 percent from fiscal 2015, an increase of 7.5 percent in constant currency while CSI’s revenues rose to $389.6 million for the year, an increase of 26 percent from fiscal 2015.

The company noted it incurred “significant expenses in connection with our acquisitions and also incurred certain other operating expenses or income, which we generally would not have otherwise incurred in the periods presented as a part of our continuing operations. Many of these costs relate to our acquisition of Sauflon Pharmaceuticals Ltd. that closed in our fiscal fourth quarter of 2014.

“Acquisition related and integration expenses include items such as personnel costs for transitional employees, other acquired employee related costs and integration related professional services. Restructuring expenses include items such as employee severance, product rationalization, facility and other exit costs,” the company said.